**S4. Deterioration in cognitive function from baseline to 2 years in persons treated with SSRI and antihypertensive drugs**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Variable** | **SSRI and other antihypertensives**  **N = 243** | **SSRI and CCB**  **N = 53** | **adjOR** | **95% CI** | **P** |
|  | **N(%) with decline** | **N(%) with decline** |  |  |  |
| MMSE | 30 (12.3) | 9 (17.0) | 1.61 | .66-1.05 | .29 |
| IST | 30 (12.3) | 7 (13.2) | 1.35 | .53-3.44 | .53 |
| BVRT | 37 (15.2) | 8 (15.130 | .92 | .38-2.22 | .84 |
| TMT-B/A | 18 (7.4) | 6 (11.3) | 1.52 | .54-4.29 | .43 |

*adjOR, adjusted odds ratio; BVRT, Benton Visual Retention Test; CCB, calcium channel blocker; CI, confidence interval; IST, Isaac’s Set Test; MMSE, Mini Mental State Examination; SSRI, selective serotonin re-uptake inhibitor; TMT, Trail Making Test ratio of time to complete part B/A; Adjusted for propensity score, age, sex and education*

*Other antihypertensives inclusive of angiotensin converting enzyme inhibitors, angiotensin-2 receptor blockers, beta-blockers, thiazides*